SLC5A2 and type 2 diabetes mellitus: Propensity score (PS) matched (1:1) adults with type 2 diabetes (T2D) initiating empagliflozin (a sodium-glucose cotransporter-2 inhibitor) during 2014–2018 who were compared to those initiating a dipeptidyl peptidase-4 inhibitor (DPP-4i).